• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.

作者信息

Zang Jinkai, Gu Chenjian, Zhou Bingjie, Zhang Chao, Yang Yong, Xu Shiqi, Bai Lulu, Zhang Rong, Deng Qiang, Yuan Zhenghong, Tang Hong, Qu Di, Lavillette Dimitri, Xie Youhua, Huang Zhong

机构信息

CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200031, China.

出版信息

Cell Discov. 2020 Sep 3;6:61. doi: 10.1038/s41421-020-00199-1. eCollection 2020.

DOI:10.1038/s41421-020-00199-1
PMID:32901211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7471522/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2393/7471949/945008bea6bd/41421_2020_199_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2393/7471949/945008bea6bd/41421_2020_199_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2393/7471949/945008bea6bd/41421_2020_199_Fig1_HTML.jpg

相似文献

1
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.用严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体结合域进行免疫接种可引发交叉中和SARS-CoV-2和SARS-CoV的抗体，且不存在抗体依赖的增强作用。
Cell Discov. 2020 Sep 3;6:61. doi: 10.1038/s41421-020-00199-1. eCollection 2020.
2
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
3
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.恢复期供体的 SARS-CoV-2 抗体的增强作用与中和作用与 RBD 上的不同表位相关。
Cell Rep. 2021 Feb 2;34(5):108699. doi: 10.1016/j.celrep.2021.108699. Epub 2021 Jan 12.
4
Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.鉴定一种中和抗体，该抗体识别 SARS-CoV-2 刺突受体结合结构域紧邻受体结合界面的环区。
Microbiol Spectr. 2024 Apr 2;12(4):e0365523. doi: 10.1128/spectrum.03655-23. Epub 2024 Feb 28.
5
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.SARS-CoV-2 刺突蛋白中与 ACE2 和中和抗体相互作用的受体结合基序的关键残基。
Cell Mol Immunol. 2020 Jun;17(6):621-630. doi: 10.1038/s41423-020-0458-z. Epub 2020 May 15.
6
Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.针对刺突受体结合域中特定表位的单克隆抗体对 SARS-CoV-2 感染的中和或增强作用。
Antiviral Res. 2022 Apr;200:105290. doi: 10.1016/j.antiviral.2022.105290. Epub 2022 Mar 13.
7
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.康复者中 SARS-CoV-2 感染的性别差异和中和抗体持久性。
mSphere. 2021 Aug 25;6(4):e0027521. doi: 10.1128/mSphere.00275-21.
8
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.针对 SARS-CoV-2 受体结合域的中和抗体，该抗体源自一个原始的人源抗体文库。
Protein Sci. 2021 Apr;30(4):716-727. doi: 10.1002/pro.4044. Epub 2021 Feb 24.
9
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.鼻喷奥密克戎疫苗加强针引发针对新型 SARS-CoV-2 变异株的强烈中和抗体应答。
Emerg Microbes Infect. 2022 Dec;11(1):964-967. doi: 10.1080/22221751.2022.2053365.
10
Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.佐剂化的 SARS-CoV-2 刺突蛋白在小鼠单次免疫后可引发中和抗体和 CD4 T 细胞应答。
EBioMedicine. 2021 Jan;63:103197. doi: 10.1016/j.ebiom.2020.103197. Epub 2021 Jan 7.

引用本文的文献

1
Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses.通过皮肤贴片递送的新冠病毒刺突DNA疫苗可产生广泛的中和抗体反应。
Heliyon. 2025 Feb 7;11(4):e42533. doi: 10.1016/j.heliyon.2025.e42533. eCollection 2025 Feb 28.
2
Antibody-dependent enhancement of coronaviruses.冠状病毒的抗体依赖性增强作用。
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
3
Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects.

本文引用的文献

1
A human monoclonal antibody blocking SARS-CoV-2 infection.一种人源单克隆抗体阻断 SARS-CoV-2 感染。
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
2
COVID-19 vaccine design: the Janus face of immune enhancement.COVID-19 疫苗设计：免疫增强的两面性。
Nat Rev Immunol. 2020 Jun;20(6):347-348. doi: 10.1038/s41577-020-0323-4. Epub 2020 Apr 28.
3
SARS-CoV-2 Vaccines: Status Report.SARS-CoV-2 疫苗：现状报告。
将 COVID-19 疫苗技术从关键质量属性转移到伊朗后的临床和免疫原性方面的比较评估。
Sci Rep. 2024 Nov 5;14(1):26793. doi: 10.1038/s41598-024-77331-8.
4
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.异源mRNA/MVA递送三聚体RBD作为针对SARS-CoV-2的有效疫苗接种方案：COVARNA联盟
Emerg Microbes Infect. 2024 Dec;13(1):2387906. doi: 10.1080/22221751.2024.2387906. Epub 2024 Aug 8.
5
An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.一种免疫受体靶向策略，融合最小化的 C3b 肽，增强了 SARS-CoV-2 RBD mRNA 疫苗的免疫原性。
Int J Nanomedicine. 2024 Jul 17;19:7201-7214. doi: 10.2147/IJN.S463546. eCollection 2024.
6
Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.利用预先存在的流感病毒特异性免疫力可增强针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体反应。
J Virol. 2024 Feb 20;98(2):e0157123. doi: 10.1128/jvi.01571-23. Epub 2024 Jan 11.
7
A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.一种原始噬菌体展示文库衍生的纳米抗体中和 SARS-CoV-2 及其三种关注变体。
Int J Nanomedicine. 2023 Oct 16;18:5781-5795. doi: 10.2147/IJN.S427990. eCollection 2023.
8
Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein.编码RBD-PVXCP融合蛋白的新型冠状病毒2 DNA疫苗的设计与免疫原性
Vaccines (Basel). 2023 May 23;11(6):1014. doi: 10.3390/vaccines11061014.
9
SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice.与聚葡萄糖、亚精胺和双链RNA偶联的新型冠状病毒刺突蛋白受体结合域在小鼠中引发强烈免疫反应。
Vaccines (Basel). 2023 Apr 6;11(4):808. doi: 10.3390/vaccines11040808.
10
Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel85 Protects K18-hACE2 Mice against Lethal Virus Challenge.嗜热丝状真菌C1细胞克隆的严重急性呼吸综合征冠状病毒2刺突受体结合域亚单位疫苗与Aldydrogel85佐剂联合使用可保护K18-hACE2小鼠免受致命病毒攻击。
Vaccines (Basel). 2022 Dec 11;10(12):2119. doi: 10.3390/vaccines10122119.
Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.
4
The SARS-CoV-2 Vaccine Pipeline: an Overview.严重急性呼吸综合征冠状病毒2型疫苗研发进展概述
Curr Trop Med Rep. 2020;7(2):61-64. doi: 10.1007/s40475-020-00201-6. Epub 2020 Mar 3.
5
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
6
Prospects for a MERS-CoV spike vaccine.MERS-CoV 刺突疫苗的前景。
Expert Rev Vaccines. 2018 Aug;17(8):677-686. doi: 10.1080/14760584.2018.1506702. Epub 2018 Aug 9.
7
Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.利用由单一共识登革热包膜序列组成的亚单位疫苗来阐述针对登革热病毒的四价抗体反应。
Vaccine. 2017 Nov 1;35(46):6308-6320. doi: 10.1016/j.vaccine.2017.09.063. Epub 2017 Oct 4.
8
Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.新兴或重新出现病毒的刺突蛋白受体结合域作为抗病毒疫苗开发的靶点。
Emerg Microbes Infect. 2012 Aug;1(8):e13. doi: 10.1038/emi.2012.1. Epub 2012 Aug 8.
9
A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.四价重组登革热病毒结构域 III 蛋白疫苗可刺激小鼠产生中和抗体和增强抗体。
Vaccine. 2010 Nov 29;28(51):8085-94. doi: 10.1016/j.vaccine.2010.10.004. Epub 2010 Oct 16.
10
Vaccine-induced enhancement of viral infections.疫苗诱导的病毒感染增强。
Vaccine. 2009 Jan 22;27(4):505-12. doi: 10.1016/j.vaccine.2008.10.087. Epub 2008 Nov 18.